Cage Pharma is a pre-clinical biopharmaceutical company focused on developing drugs that target tumor metabolism to enhance therapeutic efficacy. By addressing the metabolic vulnerabilities of cancer cells, Cage Pharma aims to improve treatment outcomes for patients with various malignancies.
Funding
$137.5K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer cells exhibit altered metabolic pathways compared to normal cells, creating vulnerabilities that can be exploited for therapeutic intervention. Traditional cancer treatments often fail to fully address these metabolic adaptations, leading to incomplete responses and the development of resistance.
Solution
Cage Pharma is developing targeted therapies that disrupt the unique metabolic processes of tumor cells, thereby enhancing the effectiveness of existing cancer treatments. By selectively targeting these metabolic vulnerabilities, Cage Pharma's drugs aim to improve treatment outcomes and reduce the likelihood of resistance. Their approach focuses on identifying and inhibiting key metabolic enzymes and pathways that are essential for cancer cell survival and proliferation. This strategy aims to create a more effective and durable response to cancer therapy.
Target Audience
The primary target audience includes pharmaceutical companies seeking to expand their oncology pipeline with novel therapeutic approaches, as well as clinical researchers investigating cancer metabolism and drug resistance.
Features
- Focus on pre-clinical drug development targeting tumor metabolism
- Identification of specific metabolic vulnerabilities in cancer cells
- Development of therapies to inhibit key metabolic enzymes and pathways
- Aims to enhance the efficacy of existing cancer treatments